Jorge Santos da Silva

Stories

MoonLake's Nanobody drug clears its second Phase 3 test

As of August 2026: Leading MoonLake through its first regulatory filing

MoonLake's experimental drug sonelokimab hit its main goal in a second late-stage trial, this time in psoriatic arthritis. The win moves the small Swiss biotech's Nanobody drug closer to two separate markets.

Updated Aug 10

MoonLake pushes sonelokimab toward FDA approval for a painful skin disease

New Capabilities

As of June 2026: Leading the company's first push for FDA approval

Hidradenitis suppurativa causes painful, recurring abscesses in the skin folds of an estimated 2 in 100 people, by MoonLake's count. For most of the past decade, one drug controlled it well enough to win U.S. approval.

Updated Jun 23

Notable Quotes

The breadth of response across clinical, functional and patient-reported outcomes reinforces sonelokimab's potential to become a leading treatment option.

from MoonLake's Nanobody drug clears its second Phase 3 test · Updated Aug 10

The final Week 52 data from the VELA program confirm the strength of SLK across most, if not all, metrics that matter in HS: strong early efficacy, sustained and leading improvement over time, a consistent safety profile and great convenience in dosing.

from MoonLake pushes sonelokimab toward FDA approval for a painful skin disease · Updated Jun 23